The first case of mitoxantrone exposure in early pregnancy.
Mitoxantrone is an antineoplastic agent considered a potential human teratogen because of its mechanism of action and is classified by the US Food and Drug Administration in pregnancy category risk D. In the literature there are only four cases of women exposed to the drug in late pregnancy. We report the first case of mitoxantrone therapy in the first trimester and during the pregnancy. A 41-year-old woman affected with multiple sclerosis, conceived during therapy and continued mitoxantrone until 29 weeks and 3 days of her pregnancy. She delivered by cesarean section at 39 weeks a growth restricted female baby weighing 1950g without evidence of congenital malformations.
De Santis
M
M
Telefono Rosso, Teratogen Information Service, Institute of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy. marcodesantis@rm.unicatt.it
Straface
G
G
Cavaliere
A F
AF
Rosati
P
P
Batocchi
A P
AP
Caruso
A
A
D000328:Adult; D000700:Analgesics / Q000009:adverse effects* / Q000627:therapeutic use; D001034:Apgar Score; D005260:Female; D005317:Fetal Growth Retardation / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008942:Mitoxantrone / Q000009:adverse effects* / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy; D016104:Oligohydramnios / Q000139:chemically induced / Q000473:pathology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced* / Q000503:physiopathology; D011261:Pregnancy Trimester, First
D000700:Analgesics; D008942:Mitoxantrone